These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11353600)

  • 21. Naltrexone implants as treatment for heroin dependence: part I.
    Byrne A; Graham G; Hallinan R; Murnion B
    Addict Biol; 2005 Jun; 10(2):201; author reply 201-2. PubMed ID: 16191674
    [No Abstract]   [Full Text] [Related]  

  • 22. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?
    Ramanathan S; Panksepp J; Johnson B
    Psychosomatics; 2012; 53(6):591-4. PubMed ID: 22480625
    [No Abstract]   [Full Text] [Related]  

  • 23. Naltrexone implants as treatment for heroin dependence: part II.
    Wodak A; Graham R
    Addict Biol; 2005 Jun; 10(2):202; author reply 202-4. PubMed ID: 16201030
    [No Abstract]   [Full Text] [Related]  

  • 24. A case of kleptomania and compulsive sexual behavior treated with naltrexone.
    Grant JE; Kim SW
    Ann Clin Psychiatry; 2001 Dec; 13(4):229-31. PubMed ID: 11958364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Naltrexone--high expectations to low dosages].
    Raknes G; Giverhaug T
    Tidsskr Nor Laegeforen; 2011 May; 131(8):844-6. PubMed ID: 21556092
    [No Abstract]   [Full Text] [Related]  

  • 26. Strategies to maximize the efficacy of naltrexone for alcohol dependence.
    O'Malley SS
    NIDA Res Monogr; 1995; 150():53-64. PubMed ID: 8742772
    [No Abstract]   [Full Text] [Related]  

  • 27. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence.
    Anton RF
    Pharmacogenomics; 2008 Jun; 9(6):655-8. PubMed ID: 18518841
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs.
    Dodman NH; Shuster L; White SD; Court MH; Parker D; Dixon R
    J Am Vet Med Assoc; 1988 Oct; 193(7):815-9. PubMed ID: 3192459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence.
    O'Brien CP
    Curr Psychiatry Rep; 2005 Oct; 7(5):327-8. PubMed ID: 16216149
    [No Abstract]   [Full Text] [Related]  

  • 30. Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): A case series.
    Riquelme-Mc Loughlin C; Riera-Monroig J; Morgado-Carrasco D; Giavedoni P; Podlipnik S; Iranzo P; Mascaró JM
    J Am Acad Dermatol; 2019 Aug; 81(2):644-646. PubMed ID: 31002846
    [No Abstract]   [Full Text] [Related]  

  • 31. Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric Panniculitis.
    Roginsky G; Alexoff A; Ehrenpreis ED
    J Clin Gastroenterol; 2015 Oct; 49(9):794-5. PubMed ID: 26280708
    [No Abstract]   [Full Text] [Related]  

  • 32. Naltrexone treatment of self-injurious thoughts and behaviors.
    Sonne S; Rubey R; Brady K; Malcolm R; Morris T
    J Nerv Ment Dis; 1996 Mar; 184(3):192-5. PubMed ID: 8600226
    [No Abstract]   [Full Text] [Related]  

  • 33. Naltrexone (vivitrol)--a once-monthly injection for alcoholism.
    Med Lett Drugs Ther; 2006 Jul; 48(1240):63-4. PubMed ID: 16874283
    [No Abstract]   [Full Text] [Related]  

  • 34. [Long-acting naltrexone--a new way out of opiate addiction?].
    Stavseth LS; Kunøe N; Tanum L
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2231-2. PubMed ID: 24226324
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of naltrexone upon self-injurious behavior, learning and activity: a case study.
    Taylor DV; Hetrick WP; Neri CL; Touchette P; Barron JL; Sandman CA
    Pharmacol Biochem Behav; 1991 Sep; 40(1):79-82. PubMed ID: 1780350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naltrexone implants.
    Warhaft N
    Anaesth Intensive Care; 2003 Oct; 31(5):592-3. PubMed ID: 14601290
    [No Abstract]   [Full Text] [Related]  

  • 37. Lack of information in naltrexone study.
    Rastegar DA
    Arch Gen Psychiatry; 2007 Jul; 64(7):865; author reply 865. PubMed ID: 17606820
    [No Abstract]   [Full Text] [Related]  

  • 38. Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury.
    Sandman CA; Hetrick W; Talyor D; Marion S; Chicz-DeMet A
    Peptides; 2000 Jun; 21(6):785-91. PubMed ID: 10958998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone in autistic children: behavioral symptoms and attentional learning.
    Campbell M; Anderson LT; Small AM; Adams P; Gonzalez NM; Ernst M
    J Am Acad Child Adolesc Psychiatry; 1993 Nov; 32(6):1283-91. PubMed ID: 8282676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical effects of naltrexone on autistic behavior.
    Zingarelli G; Ellman G; Hom A; Wymore M; Heidorn S; Chicz-DeMet A
    Am J Ment Retard; 1992 Jul; 97(1):57-63. PubMed ID: 1497864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.